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Abstract Purpose: A33 antigen is a membrane-bound protein expressed in intestinal epithelium that is 
overexpressed in 95% of primary and metastatic colorectal carcinomas but is absent in most 
epithelial tissues and tumor types. We hypothesized that A33 promoter might be useful in the 
design of a conditionally replicative adenovirus for the treatment of colorectal cancer (CRC). 
Experimental Design: We cloned an A33 promoter fragment (A33Pr) that extends from -105 
to +307 bp. Using luciferase activity as a reporter gene, we showed that A33 Pr was active in CRC 
cell lines. We next constructed a conditionally replicative adenovirus named AV22EL where E1A 
was placed under the control of A33Pr. The tumor-specific oncolytic effect of AV22EL was 
investigated both in vitro and in vivo.
Results: AV22EL induced specific in vitro lysis of human CRC cell lines that expressed A33 and 
have negligible lytic capacity on cells that lacked or had minimal A33 expression, including normal 
human colonic cells. In vivo, a marked reduction of tumor growth and increased long-term 
survival rates were observed in nude mice xenografted with s.c. CRC tumors. Combination with 
5-fluorouracil induced an additive effect in vitro with no toxic effects in vivo. Remarkably, AV22EL 
completely eliminated established hepatic metastases in >90% of mice and restored hepatic 
function according to biochemical parameters. Its systemic administration induced E1A 
expression only in the hepatic metastasis but not in normal organs.
Conclusions: These data show that AV22EL is a stringently regulated and potent oncolytic 
agent for the treatment of CRC.
Colorectal cancer (CRC) is the second most common cause of 
cancer mortality in Western countries and claimed >50,000 
lives a year only in the United States.4 Close to 70% of patients 
that are affected by colorectal carcinoma undergo surgical 
resection and 30% to 40% of them develop a recurrent disease 
(1). The liver is the most common site of metastatic CRC and 
complete resection of hepatic metastases is the only curative 
option; however, surgery can be done only in 20% of patients
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at the time of diagnosis and 5-year survival rates average 25% to 
40% despite adjuvant chemotherapy (2). Among patients with 
metastatic colorectal carcinoma receiving as first-line chemo­
therapy 5-fluorouracil (5-FU) and new medications, such as 
irinotecan, Xeloda, oxaliplatin, Erbitux, and Avastin, the 
median time to progression is 8 to 9 months and their mean 
survival is 15 to 20.5 months (3-6). It seems therefore that 
current CRC treatments are rather ineffective on advanced 
disease, showing the need for more effective and specific 
therapeutics to significantly increase patients' survival.
Conditionally replicative oncolytic adenoviruses (CRAd) 
have shown promising applications in cancer gene therapy 
(7, 8). One strategy to achieve specific elimination of the tumor 
mass, avoiding negative undesired effects in contiguous normal 
tissue, is the use of tumor-selective transcriptional regulation 
to control the essential early El genes, which are required to 
transactivate the other adenoviral genes (9, 10). Several 
promoters have been used to drive adenoviral replication and 
oncolytic activity in colorectal carcinoma, including the 
carcinoembryonic antigen (CEA), the telomerase, and the 
cyclooxygenase-2 (COX-2) promoters, which might provide a 
broad spectrum of therapeutic efficacy. Despite the strong 
oncolytic efficacy of these viruses, there is still a concern about 
their stringent selectivity. CEA and COX-2 promoters were
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Translational Relevance
We provide here preclinical data about the therapeutic 
efficacy of a novel oncolytic adenoviral vector, AV22EL, 
for treatment of colorectal cancer (CRC). AV22EL replica­
tion was driven by a CRC-specific A33 antigen promoter. 
A33 is a membrane-bound protein located in the intestinal 
epithelium that is overexpressed in 95% of primary and 
metastatic CRC but is absent in most epithelial tissues and 
tumor types. A specific anti-A33 antibody is already in clin­
ical use, suggesting its clinical relevance. AV22EL induced 
specifically the in vitro lysis of cells of CRC origin while 
showing almost no lytic activity on other cancer cell lines. 
AV22EL exhibited no cytocidal effect on normal human 
colonic cells and hepatocytes, whereas these cells were 
eliminated by wild-type adenovirus. AV22EL markedly 
reduced the in vivo growth in nude mice of established 
CRC and showed an additive effect in vitro when combined 
with 5-fluorouracil with no evidence of further toxic effects 
in vivo. Its systemic administration induced the disappear­
ance of hepatic metastatic nodules in >90% of mice and 
restored normal levels of hepatic enzymes following metas­
tases disappearance, exhibiting no evidence of viral activity 
in normal organs, including normal intestine, as assessed by 
E1A and luciferase expression. Thus, AV22EL fulfills the 
criteria to become a useful and strongly specific tool for 
treatment of patients with CRC.
shown to be active in CEA-negative and COX-2 - negative cells, 
respectively (11-13), the telomerase promoter could be active 
in CD34+ and other progenitors cells (14), whereas the use of 
an oncolytic virus based on the COX-2 promoter could be 
hampered by the rise of COX-2 expression in transient or 
chronic inflammation (15). An oncolytic virus was also 
designed based on a wnt-responding element because this 
pathway is strongly up-regulated in CRC; however, the wnt 
pathway is also active in normal stem cells in skin, the 
hematopoietic system, and in intestine, as well as in neurons in 
several brain regions (16), although adenovirus hardly infects 
kératinocytes and hematopoietic cells, diminishing the risks for 
undesirable collateral effects (17, 18). However, the possibility 
of generating an oncolytic virus based on stringent, cancer 
type-specific promoter might have the advantage of its strong 
attenuation in normal organs, increasing the effectiveness for 
systemic treatment of disseminated disease.
The A3 3 antigen is a cell surface glycoprotein present only in 
the small intestine and colonic epithelium with homology to 
proteins of the immunoglobulin superfamily, such as the 
coxsackievirus and adenovirus receptor (19). In human cancer, 
A33 was found in 95% of primary and metastatic colorectal 
carcinomas, 63% of diffuse gastric cancers, 83% of intestinal- 
type gastric cancers, 50% of pancreatic cancers, and ~ 50% of 
the diffuse-type and mucinous cancers; it was absent in 
epithelial cancers, sarcomas, neuroectodermal tumors, and 
lymphoid neoplasms (20, 21). A3 3 is the first example of a 
constitutively expressed, organ-specific epithelial membrane 
antigen present in patients with gastrointestinal cancer (20). 
A3 3 seems to be expressed by normal replicating colonocytes 
located at the base of the crypt that in principle should not be 
accessible to an oncolytic virus (20). This restricted tissue 
localization and specific expression of A3 3 in gastrointestinal 
cancer led to the initiation of clinical trials in CRC aiming to 
target A33 by using specific antibody immunotherapy (22-26).
Initial data obtained from clinical studies using oncolytic 
viruses have been encouraging in terms of efficacy with 
minimal, if any, toxicity (27). However, their efficacy in the 
treatment of systemic metastasis remains a major challenge. We 
hypothesized that the A33 promoter (A33Pr) might be useful in 
the design of a CRAd. Thus, we constructed a new CRAd 
(AV22EL) in which E1A was placed under the control of A33Pr. 
We evaluated cell selectivity and cytotoxicity in a variety of 
normal and human cancer cell lines in vitro and determined the 
antitumor activity of the oncolytic vector on established s.c. 
tumors and liver metastasis following xenotransplantation of 
human CRC cells in nude mice. The whole data show that 
AV22EL is a potent oncolytic virus that can be combined with 
current chemotherapeutic agents.
Materials and Methods
Cell lines
The human CRC (LoVo, T84, and HT29), breast cancer (T47D), 
hepatocellular carcinoma (Hep-3B2), and fetal lung fibroblast (WI-38 
and HFL-1) cell lines and cell lines derived from normal colon epithelia 
(FHC and CCD841) and human embryonic kidney cells (HER 293) 
were obtained from the American Type Culture Collection. The human 
melanoma cell lines A375N and SB2 were kindly provided by Dr. Estela 
Medrano (Efuffmgton Center on Aging, Efouston, TX), and bovine 
aortic endothelial cells were kindly provided by Efelene Sage (Univer­
sity of Washington, Seattle, WA). All the cell lines were grown in the 
recommended medium supplemented with 10% fetal bovine serum 
(Invitrogen Corp.), 2 mmol/L glutamine, 100 units/mL penicillin, and 
100 pg/mL streptomycin and maintained in a 37°C atmosphere con­
taining 5% CO2.
Assessment of A33 mRNA expression
Total RNA was extracted using Tri Reagent (Sigma-Aldrich Co.). RNA 
(5 pg) was reverse transcribed with 200 units of SuperScript II Reverse 
Transcriptase (Invitrogen) using 500 ng of oligo(dT) primers. cDNAs 
were subjected to semiquantitative PCR. Each 25 |il. reaction volume 
contained 1 unit Taq DNA polymerase (Invitrogen), 1 x PCR reaction 
buffer [20 mmol/L Tris-HCl (pH 8.4), 50 mmol/L KC1], 1.5 mmol/L 
Mg2Cl, 200 pmol/L of deoxynucleotide triphosphates, and 0.4 pmol/L 
of each specific primer. For the list of primers, see Supplementary 
Table SI. PCR conditions were set as follows: 90 s at 94°C and then 
30 cycles of 30 s at 94°C, 30 s at 60°C, and 30 s at 72°C. All the 
reactions were done in triplicates, and the results obtained for A33 were 
normalized to glyceraldehyde-3-phosphate dehydrogenase.
Construction of AV22EL and other recombinant adenoviruses
A 412-bp fragment of the human A33 promoter region (-105 to +307 
bp relative to the transcription start site) was amplified from human 
lymphocyte genomic DNA using specific primers (Supplementary 
Table SI). The PCR product was cloned in pGEM-T easy vector 
(Promega Corp.) followed by subcloning in the Bg/II/X/ioI sites of 
the promoterless firefly luciferase gene reporter vector pGL3-Basic 
(Promega) to obtain pGL3-A33.
We replaced the Rous sarcoma virus promoter of the shuttle vector 
pADPSY (28) with a multiple cloning site (Spel, Bell, Kpnl, Nhel, Mini, 
Bglll, I'coKV, Clal, SnaBI, and Sal I) to create pAd-Xp. Next, a 234-bp 
fragment corresponding to the stop codon region of the growth 
hormone gene (29) was PCR cloned in the Spel Kpnl sites downstream 
of the inverted terminal repeat to create a new shutde vector named 
pAd-I-Xp (see Supplementary Table SI for the list of primers). A
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+560/+l,632-bp fragment of E1A genomic sequence was PCR cloned 
from 293 cells, subcloned in TOPO-pCR4, and sequenced (see Sup­
plementary Table SI). After subcloning in pcDNA3, HeLa cells were 
transfected to express E1A that was identified using a specific anti-ElA 
antibody (M73; Santa Cruz Biotechnology). A Bglll/BfiinHI E1A frag­
ment was subcloned into the Bg/II site of pAd-I-Xp followed by clon­
ing of A33Pr upstream of E1A in Mlul/Bglll sites to obtain the shutde 
plasmid pAd-I-A33-ElA. The identity of the final construct was con­
firmed by sequencing. To construct AV22EL, the cotransfection method 
in 293 cells was used (30). Adenovirus amplification and purification 
were done as described (31). Physical particle concentration [viral par­
ticles (vp)/mL] was determined by A2go reading and biological particle 
concentration [determination of 50% tissue culture infective dose 
(TCID50)] was determined by standard plaque assay on 293 cells (31).
Obtention of pAd-SV40-luc, pAd-CMV-Rem/ki, and pAd-AV-Luc 
vectors is described in Supplementary Data. Viral stocks were obtained 
after cotransfection in HER 293 cells as above.
Luciferase assays
Luciferase assay using plasmids. Cells seeded in 24-well plates 
(4 x 104 per well) were cotransfected with 0.8 pg of plasmid expressing 
luciferase as a reporter gene and 0.1 pg of pRL-CMV (Promega) using 
Lipofectamine 2000 (Invitrogen). Cells were harvested 46 h later and 
the dual luciferase assay was done following the manufacturer's recom­
mendations (Promega). Luciferase activity was measured using a GENios 
luminometer (TECAN). Data are expressed as fold induction over pGL3- 
Basic vector and obtained from at least three independent experiments.
In vitro luciferase assay using adenovirus. Cells seeded in 24-well 
plates (4 x 104 per well) were transduced with AV-Luc [multiplicity of 
infection (MOI), 100] and Ad-CMV Renilla (MOI, 10) in 200 pL of 
DMEM/F12 containing 2% fetal bovine serum. Fresh medium contain­
ing serum (800 pL) was added 2 h later followed by cell harvesting after 
48 h. Quantification of luciferase activity followed the manufacturer's 
recommendations (Promega). Luciferase activity was measured using 
a GENios luminometer. The luciferase activity was normalized by 
Ad-CMV Renilla activity.
In vivo luciferase assay using adenovirus. L0V0 cells (5 x IO6) were 
injected s.c. and allowed to form tumors in the flank of 5- to 6-wk-old 
athymic N:NIH (S)-nu mice. When the average tumor volume reached 
100 mm3, mice received 1 x 1010 vp/mouse of AV-Luc administered 
through the tail vein. Forty-eight hours later, luciferase activity in 
various tissues and in the liver metastatic nodules was determined. 
Quantification of luciferase activity followed the manufacturer's re­
commendations (Promega). Luciferase activity was measured using a 
GENios luminometer. The luciferase activity was normalized by milli­
gram of protein Ad.
/’-Galactosidase staining assay
Cell infectivity was assessed using an adenovirus expressing the 
bacterial p-galactosidase protein (Ad-pgal). Twenty-four hours after 
plating, cells were infected with Ad-pgal at different MOI in serum-free 
medium for 42 h, and the cells were incubated for an additional 72 h in 
DMEM/F12 containing 10% fetal bovine serum. Infected cells were 
washed with PBS, fixed, and evaluated for p-galactosidase activity 
by incubation in 5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside 
(X-Gal) staining solution (32).
Assessment of E1A levels
For determination of E1A mRNA levels, 1.5 x 105 cells per well were 
seeded in a six-well plate. The next day, cells were infected with the indicated 
viruses at 1,000 MOI or mock infected. After 24, 48, and 72 h, cells were 
lysed and total RNA was obtained. A semiquantitative PCR for E1A was 
done using the set of primers described in Supplementary Table SI.
Western blot
L0V0 cells were transduced with AV22EL or Ad-WT (kindly provided 
by Dr. Andre Lieber, Seatde, WA) at various MOIs. After 72 h, total 
protein extracts were prepared in lysis buffer [10 mmol/L Tris (pH 7.5), 
1 mmol/L EDTA, 150 mmol/L NaCl, 1% Triton X-100 (Sigma), 0.5% 
deoxycholic acid (Sigma), 0.1% SDS with a protease inhibitor cocktail]. 
Total protein extracts were separated in 10% SDS-PAGE and transferred 
to nitrocellulose membranes (Bio-Rad Laboratories). The membranes 
were probed with anti-ElA antibody (M73; Santa Cruz Biotech) and 
anti-p-actin antibody (A4700; Sigma) was used as a loading control. 
Enhanced chemiluminescence reagents were used to detect the signals 
following the manufacturer's instructions (Amersham).
Cytopathic effect
Cells were seeded in 24-well plates at a density of 1 x 104 per well. 
The next day, cells were infected with AV22EL or Ad-WT adenovirus at a 
MOI ranging from 1 to 1,000. The cytopathic effect was monitored by 
staining viable cells with crystal violet 10 d after infection (31). Density 
of gel bands was analyzed by using the ImageJ program developed by 
Wayne Rasband (NIH, Bethesda, MD).
T84-EGFP cells correspond to a single-cell clone obtained by limiting 
dilution after cell transfection with a plasmid expressing EGFP and 
selection in G418 (750 pg/mL). WI-38 and T84 EGFP cells were seeded 
in 24-well plates at a density of 5 x 104 per well, each. The next day, 
cells were infected with AV22EL or Ad-WT at MOI of 500. Cells were 
photographed at day 7 after the initiation of the experiment under light 
and UV microscope. At the end of the experiments, cells were counted 
in a Neubauer chamber under light and UV microscope. The experi­
ments were done thrice.
Hepatocyte isolation
Liver samples were collected from one patient undergoing partial 
hepatectomy. Sample collection was obtained under informed consent 
with the approval of the ethics committee of the Hospital University 
Austral. Hepatocyte isolation was done under sterile conditions using a 
modified two-step collagenase perfusion technique (33). Liver samples 
were homogenized with 0.1% collagenase for 30 min, twice. Cell 
suspension was centrifuged at 50 X g for 5 min at 4°C. The cells were 
purified by density gradient centrifugation (1,278 x g, 20 min, 4°C) 
using a 25% Percoll solution (density of 1.124 g/mL) in cold PBS. After 
isolation, hepatic cells were counted and viability was assessed by 
trypan blue exclusion test. Cells were seeded in collagen type I. At day 5, 
glycogen storage was detected by procedure periodic acid-Schiff.
In vitro assays combining AV22EL with 5-FU
Cells seeded in 96-well plates (2 X 103 per well) were infected the 
next day with AV22EL or treated with 5-FU (Microsules Bernabo). In 
one experimental condition, cells were first treated with 5-FU for 24 h, 
the medium was then removed, and the cells were transduced with 
AV22EL. In another experimental condition, cells were first infected 
with AV22EL for 24 h and then the medium was replaced with fresh 
medium containing 5-FU. Five days after treatment, cell viability was 
established with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo- 
lium bromide (MTT) assay and the absorbance was read at 570 nm 
using a Bio-Rad Model 550 microplate reader (Bio-Rad Laboratories). 
All assays were carried out in six different replicates.
Multicellular spheroids
The semisolid liquid overlay culture technique was used to produce 
multicellular spheroid cultures (34). Briefly, 1 x 104 cells were seeded 
onto a semisolid 1% (w/v) agarose per well layer in 96-well plates in 
200 |1L of medium. Seventy-two-hour-old spheroids were infected at 
MOIs of 10, 100, and 500 for 7 d with the different adenoviruses. At the 
end of the experiment, spheroids were photographed and growth was 
quantified by regular measurement of cross-sectional area of individual 
spheroids.
Virus yield
Six-well plates were seeded with 1 X 105 cells per well 24 h before 
infection. Cells were infected at a MOI of 50 for 2 h in serum-free
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medium. Then, the virus-containing media were removed, monolayers 
were washed twice with PBS, and 1 mL of complete medium was added 
to each well. At 72 h after infection, the cells were scraped into culture 
medium and lysed by three cycles of freezing and thawing. The 
supernatant was tested for the viral titer by an end point cytocidal assay 
as described by Li et al. (35).
In vivo studies on s.c. tumors and hepatic metastases
Five- to 6-wk-old female and male athymic N:NIH (S)-nu mice 
(obtained from the animal facility of the Faculty of Veterinary, 
University of La Plata) were s.c. injected in one flank with 5 x IO6 
cells. When the average tumor volume reached 100 mm3, mice received 
1 x IO10 vp/mouse of AV22EL or vehicle administered intratumorally 
on days 1, 4, and 7. For in vivo assays combining AV22EL with 5-FU, 
mice were injected with AV22EL followed by i.p. administration of 
5-FU (30 mg/kg for 5 d) starting 1 d after the last AV22EL injection. 
Tumor volumes were estimated twice a week from caliper measure­
ments [volume = 0.52 x (width)2 x length]. In vivo experiments were 
done following institution guidelines approved by the NIH, and all 
animals under study received food and water ad libitum. For colorectal 
liver metastases studies, LoVo cells (1 x IO6) were injected via the 
portal vein of female and male nude mice. At day 7 after cell 
inoculation, when multiple tiny spots of tumor metastases were 
confirmed in parallel experimental groups, mice received tail vein 
injections of AV22EL, Ad-pgal, or vehicle. Administration was repeated 
48 and 72 h later. Animals were bled and serum was used to determine 
albumin, aspartate aminotransferase, and alkaline phosphatase levels.
For assessment of E1A expression in vivo, mice, harboring or not 
established liver metastases, were injected once via the tail vein with 
AV22EL or PBS. Three days later, mice were sacrificed and organs were 
removed for obtention of total RNA.
For in vivo detection of viral replication, hepatic metastases were 
fixed in 4% paraformaldehyde for 1 h, cryopreserved overnight in 30% 
sucrose, embedded in tissue OCT, and stored at -20°C. Cryostat 
sections (9 pm) were mounted on gelatin-coated slides and incubated 
with goat anti-adenoviral hexon protein antibody AB1056 (Chemicon 
International). Biotinylated secondary antibodies were used in con­
junction with the Vectastain avidin-biotin complex method kit 
(Vector Laboratories), and finally, the reaction was visualized by using 
3,3'-diaminobenzidine chromogen (Dako). Slides were counterstained 
with hematoxylin and photographed on an Olympus BX60 microscope. 
The liver metastasis was sectioned in three pieces, each - 0.5 mm in 
width. Histologic analysis was done on one 5-pm tissue section of each 
piece.
Assessment of intratumor viral replication
LoVo cells (5 x 106) were injected s.c. and allowed to form tumors in 
the flank of 5- to 6-wk-old athymic N:NIH (S)-nu mice. When the 
average tumor volume reached 100 mm3, mice received 1 x 1010 
vp/mouse of AV-Luc or AV22EL administered intratumorally on day 1. 
Seven days after injection, total DNA was obtained from tumors 
(Illustra tissue & cells genomicPrep Mini Spin, GE Healthcare) and E4 
gene was measured by quantitative real-time PCR (36, 37). Genomic 
DNA was subjected to real-time PCR in an iCycler iQ System (Bio-Rad 
Laboratories). Each 25 |iL reaction volume contained 1 unit Platinum 
Taq DNA polymerase (Invitrogen), 1X PCR reaction buffer [20 mmol/L 
Tris-HCl (pH 8.4), 50 mmol/L KC1], 1.5 mmol/L Mg2Cl, 2.5 g bovine 
serum albumin, 0.01% glycerol, 0.4 pmol/L of each specific primer 
targeting the E4 region (Ad5, nucleotides 33806-34074; Supplementary 
Table SI), 200 pmol/L of deoxynucleotide triphosphates, and 0.3X 
SYBR Green Solution. PCR conditions were set as follows: 150 s at 94°C 
and then 39 cycles of 45 s at 94°C, 30 s at 60°C, and 30 s at 72°C. All 
the reactions were done in triplicate. Analysis of data was carried out 
using the iCycler software (Bio-Rad Laboratories) by comparing test 
sample with a standard. Standard curves were generated by serial 
dilutions of 1010 copies of adenoviral DNA in a solution of control 
cellular genomic DNA.
Statistical analysis
Statistical analyses of luciferase studies, spheroids, and in vivo 
experiments were determined by ANOVA followed by Tukey's test. 
Statistical analyses of 5-FU curves and viral replication in vivo were 
determined by ANOVA (two-way ANOVA) followed by Bonferroni's 
test. AP value of <0.05 was considered significant. Statistical analyses of 
serum liver chemistries were done by the Dunnett's multiple 
comparison test. Survival was determined by the method of Kaplan- 
Meier. Log-rank test was used to compare differences in survival. 
Data analysis was done with the GraphPad Prism (GraphPad Software, 
Inc.).
Results
Analysis of A33 mRNA expression and A33 promoter activity 
in different human cell lines. To establish whether A33 gene 
promoter could be useful for the construction of a CRAd, we 
first evaluated A3 3 mRNA expression levels in different 
malignant and normal human cells by semiquantitative PCR. 
Only colorectal carcinoma cell lines LoVo, T84, and HT29 
showed A33 mRNA expression, whereas normal colonic cells 
CCD841 showed approximately one tenth the levels of A33 
mRNA observed in LoVo cells (Fig. 1A). A33 mRNA was not 
expressed in additional malignant cells, normal fibroblasts, and 
endothelial cells (Fig. 1A). A33Pr, cloned in the promoterless 
plasmid pGL3 basic, was essentially active only in human CRC 
cells LoVo, T84, and HT29, whereas human mammary and 
melanoma cells showed strongly reduced activity (Supplemen­
tary Fig. S1A). In coincidence, an adenoviral vector expressing 
the luciferase gene driven by A33Pr (AV-Luc) was highly active 
only in CRC cells; among A3 3-nonexpressing cells, AV22EL 
showed a slight activity in SB2 melanoma cells (Fig. IB and see 
below).
We next constructed a CRAd (AV22EL) where El A was placed 
under the control of A33Pr (Supplementary Fig. SIB). AV22EL 
genome lacks the adenoviral E3 region and contains the I- 
A33Pr-ElA cassette introduced in the El region of the viral 
backbone. E1A expression driven by A33Pr was confirmed by 
Western analysis after transduction of LoVo cells at different 
MOIs of AV22EL (Fig. 1C).
Selective replication and lytic activity of AV22EL in CRC 
cells. AV22EL showed marked in vitro cytocidal effect against 
LoVo and T84 human CRC cells expressing the highest A33 
mRNA levels (Fig. 2A and B). AV22EL was at least 2 orders of 
magnitude less effective on HT29 human colorectal carcinoma 
cells that expressed the lowest A3 3 mRNA level among the CRC 
cells (Fig. 2A and B). Interestingly, the presence of the E3 region 
was slightly detrimental for the in vitro lytic activity of the 
A33Pr-based CRAd (Supplementary Fig. S2A). AV22EL was 
only effective at 1,000 MOI on human Hep-3B hepatoma and 
SB2 melanoma cells, whereas it had essentially no cytocidal 
effect on human A375 melanoma cells, T47D breast cancer 
cells, WI-38 and HFL-1 fibroblasts, and bovine aortic endothe­
lial cells (Fig. 2A and B). Ad-WT was active in CRC cells at a 
lower MOI than AV22EL (Fig. 2A and B; Supplementary 
Fig. S2B); however, its lytic activity was independent of the 
A3 3 levels expressed by the different cell types (Fig. 2A and B).
AV22EL specificity was further confirmed when T84 CRC 
cells expressing EGFP were mixed in vitro with WI-38 
fibroblasts. Under these conditions, only T84-EGFP cells were 
lysed by AV22EL, whereas neighbor WI-38 fibroblasts were not 
affected (Supplementary Fig. S2C and D). On the other hand,
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Fig. 1. Characterization of A33 promoter activity in different cell types. A A33 mRNA levels in different cell types. A33 mRNA levels were assessed as described in Materials 
and Methods. All the experiments were done in triplicate, and the data were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels. Columns, 
mean; bars, SD. B, activity of the A33 promoter. Cells were transduced with 5 x 106 vp/mL of AV-Luc and Ad-CMV Renilla as described in Materials and Methods. Cell 
extracts were assayed 2 d later for firefly and Renilla luciferase. Columns, mean of three independent experiments; bars, SD. C, Western blot analysis showing E1A expression 
in LoVo cells infected with AV22EL.
Ad-WT efficiently lysed both cell types (Supplementary 
Fig. S2D).
As an alternative way to establish the selectivity of AV22EL, 
cells were infected with AV22EL or Ad-WT and the viral yield 
was measured by plaque assay at 72 hours after infection. 
AV22EL replicated very efficiently in LoVo and T84 colon 
cancer cells, although at a lower level than Ad-WT (Fig. 2C). On 
the other hand, AV22EL replicated inefficiently in A33- 
nonexpressing melanoma and breast cancer cell lines that 
produced 105- to 10s-fold less progeny than A33-positive cells. 
The virus did not replicate at all in normal colon cells, 
fibroblasts, and endothelial cells (Fig. 2C). Interestingly, HT29 
colon cancer cells that express A33 showed viral yield levels 
similar to those observed in SB2 melanoma cells that did not 
express A33 (Fig. 2C). Despite that, AV22EL showed 10-fold 
higher lytic capacity on HT29 cells compared with SB2. By 
using a replication-defective adenovirus expressing the 
l>-galactosidase gene followed by X-Gal staining, we observed 
that at the largest MOI of 1,000, only 40% of HT29 cells were 
transduced compared with — 100% of SB2 melanoma cells 
(Supplementary Fig. S2E). On the other hand, HT29 CRC cells 
infected with 1,000 MOI of AV22EL exhibited clearly detectable 
levels of E1A, whereas only faint levels of El A were seen in SB2 
melanoma cells under the same conditions (Supplementary 
Fig. S2F). Ad-WT infection led to similar E1A expression levels 
in both HT29 and SB2 cells (Supplementary Fig. S2F). These 
data show that AV22EL replicates in HT29 cells at a better 
extent compared with SB2 melanoma cells, although, based on 
El A expression, it seems that SB2 melanoma cells can support a 
certain level of AV22EL replication.
Complete attenuation of AV22EL lytic capacity on normal 
human colonic cells and hepatocytes. To further establish that 
AV22EL activity was attenuated in normal cells, we assessed its 
cytocidal effect on CCD841 and FHC cells derived from normal 
colon epithelia. Ad-WT efficiently lysed both LoVo colorectal 
carcinoma cells and normal colonic epithelial cells at a MOI of 
100 (Fig. 3A). However, AV22EL exerted a cytocidal effect on 
LoVo cells but had no lytic effect on CCD841 and FHC cells, 
suggesting that AV22EL is strongly attenuated in normal 
colonic cells (Fig. 3A). Of relevance was also the evidence that 
AV22EL had no lytic activity on normal human hepatocytes at 
the largest MOI of 1,000, whereas Ad-WT exhibited a strong 
lytic effect (Fig. 3B). The inset also shows that Ad-WT, but not 
AV22EL, could replicate in normal hepatocytes (Fig. 3B).
AV22EL lytic capacity on cells growing in multicellular 
spheroids. Multicellular spheroids represent a tridimensional 
in vitro model of an avascular growing tumor. Three-day-old 
spheroids were infected in situ with AV22EL or Ad-WT at 
different MOIs and followed for additional 7 days. At the end 
of the experiment, spheroids were photographed and sized. 
Zero MOI corresponds to the average volume of noninfected 
spheroids at the end of the experiment (Fig. 4; Supplementary 
Table S2). Spheroids contained in average 5,000 cells at the 
beginning of the experiment, whereas noninfected spheroids 
grew up to an average of 30,000 cells/each after 7 days 
(Supplementary Fig. S3A). In the photography, A375N 
spheroid volume seems larger due to the fact that A375N cell 
size is larger than the others (data not shown). Ad-WT inhibited 
— 50% the growth of spheroids made of A375N and SB2 
melanoma cells, whereas AV22EL had essentially no inhibitory 
effect (Fig. 4A; Supplementary Table S2). On the other hand, 
AV22EL was as effective as Ad-WT on the growth inhibition of 
spheroids made of LoVo cells (Fig. 4A; Supplementary Table 
S2). These results confirmed the selective oncolytic capacity of 
AV22EL on CRC cells.
In vivo antitumor effect of AV22EL on established tumors. 
Nude mice were initially xenotransplanted in the flank with 
tumorigenic inocula of LoVo or SB2 cells. When the average 
tumor volume reached 100 mm3, mice received 1 x 1010 vp/ 
mouse of AV22EL or vehicle administered via intratumor 
injection at days 1, 4, and 7. AV22EL was effective in 
inhibiting tumor growth in 100% of mice harboring 
established LoVo tumors (Fig. 5A, left), including complete 
tumor regression in two mice that lasted for 200 days (data 
not shown). However, AV22EL did not affect SB2 melanoma 
cell growth despite an initial inhibitory effect (Fig. 5A, left) 
that is probably in accordance with the faint El A levels 
reflecting viral replication that were observed after SB2 
infection with AV22EL (Supplementary Fig. S2F). No evidence 
of tumor growth inhibition was observed in mice harboring
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Fig. 2. AV22 EL cytocidal effect and replication capacity in different cell types. A, cytocidal effect of AV22 EL on different cell types. AV22 EL exerted a cytocidal effect 
only on LoVo,T84, and HT29 colon cancer cells, whereas Ad-WTshowed cytocidal effect on every cell type. Cells were cultured for 10 d before staining with crystal violet. 
B, quantification of crystal violet levels was assessed as described in Materials and Methods. C, virus yield study of AV22EL on different normal and tumor cell lines. 
Columns, mean; bars, SD.
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LoVo tumors treated with PBS. Kaplan-Meier curve showed 
that AV22EL-treated mice survived significantly longer than 
control mice (P < 0.01; Fig. 5A, right). There was no sign of 
virus-related toxicity or weight loss associated with the 
treatment (data not shown). To confirm that AV22EL 
replicated in situ, we injected intratumorally mice harboring 
colon cancer tumors of 100 mm3 average volumes. Seven days 
later, 1.2 x IO10 viral copies per tumor were recovered after 
AV22EL administration compared with 1.7 x 10s copies per 
tumor obtained after administration of a nonreplicating 
adenovirus expressing luciferase (AV-Luc; Fig. 5A, right).
Combination ofAV22EL with 5-FU. Because s.c. tumors were 
not completely eliminated by AV22EL treatment, we assessed 
whether the combination of AV22EL with the commonly used 
chemotherapeutic agent 5-FU will improve therapeutic efficacy. 
After initial attempts to combine AV22EL and 5-FU in different 
ways, we observed that preincubation of cells with AV22EL 
followed by washing and addition of 5 pg/mL 5-FU for 4 
additional days enhanced the lytic effect of 5-FU both on LoVo 
and HT29 cells, although in the latter the effect was less 
pronounced (Fig. 5B, a). T84 cells were highly sensitive to 5-FU 
alone (Fig. 5B, a). When 5-FU concentration was lowered to 
0.1 pg/mL, we observed that 10 MOI of AV22EL significantly 
enhanced the lytic effect of 5-FU on the three colon cancer cell 
lines compared with 5-FU alone (Fig. 5B, b). AV22EL was 
completely attenuated in normal cells because it was unable to
Fig. 3. Lack of AV22EL cytocidal effect on 
normal cells. A, lack of cytocidal effect of 
AV22EL on normal colonic cells. AV22EL 
exerted a cytocidal effect only on LoVo CRC 
cells but had no effect on CCD841 and FHC 
normal colonic cells grown as monolayers. 
Ad-WT lysed both normal and tumor 
cells. Cells were photographed under 
phase-contrast light microscope 7 d after 
the initiation of the experiment. Insets, 
crystal violet staining. B, lack of cytocidal 
effect of AV22EL on human normal 
hepatocytes. Cells obtained as described 
in Materials and Methods were infected 
with AV22EL orAd-WTand survival was 
established with the MTTassay at the end 
of the experiments. Columns, mean of 
two independent experiments with six 
replicates; bars, SD. *, statistically 
significant differences compared with 
the control (P < 0.05). Inset, viral yield 
after infection of the hepatocytes with the 
different viruses.
CCD841
100 500
AV22EL
AV22EL
100 500
AV22EL
100 500
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Fig. 4. AV22EL effects on spheroid growth. Spheroids prepared with A375N 
and SB2 human melanoma cells and LoVo CRC cells were transduced with 
increasing MOI of AV22EL orAd-WT. Photographs of the spheroids were taken 
under phase-contrast light microscopy.
enhance the growth inhibition induced by 5-FU on normal 
colon cells and fibroblasts (Fig. 5B, c).
We next evaluated if this improved inhibitory effect in vitro 
could be extrapolated in vivo. Mice harboring s.c. LoVo tumors 
were treated with PBS, 5-FU alone, AV22EL alone, or the 
combination of AV22EL followed by 5-FU. 5-FU alone did not 
significantly inhibit tumor growth (Fig. 5C), whereas mice 
treated with AV22EL induced a strong delay in tumor growth in 
100% of mice (Fig. 5C). Adding 5-FU in combination with the 
CRAd did not significantly improve the tumor growth- 
inhibitory effect observed with AV22EL alone (Fig. 5C). We 
observed no evidence of toxicity or weight loss associated with 
the treatments that included the CRAd alone or combined with 
5-FU (data not shown).
Liver metastases elimination follou’ing systemic AV22EL 
delivery. Eradication of hepatic metastases is a key factor for 
improved CRC prognosis (1). Therefore, we used an efficient 
model for metastases development in the liver by injecting 
nude mice in their portal vein with CRC cells. After we have 
confirmed that hepatic metastases developed, we assessed 
whether systemic administration of AV22EL might suppress 
growth of established tumor nodules.
Mice were treated with AV22EL, Ad-Pgal, or PBS at days 7, 10, 
and 14 after the initial cell injection. Seven days after the last 
viral administration, mice were sacrificed. Almost all the mice 
injected with Ad-Pgal or PBS developed multiple tumor 
nodules throughout the liver by day 21 after cell injection 
(Fig. 6A). Mice treated with PBS or Ad-Pgal showed metastatic 
nodules that displayed areas with glandular-like arrangement of 
tumor cells (Fig. 6A, left). Gross observation and histopatho­
logic analysis of autopsies confirmed that 10 of 11 mice 
injected with AV22EL were free of metastatic nodules (Fig. 6A, 
right), whereas 1 animal showed strongly reduced metastatic 
areas (data not shown). None of the mice injected with PBS or 
Ad-Pgal showed evidence of therapeutic benefit (Fig. 6A, right). 
In addition, abundant expression of the adenovirus hexon 
protein was detected in tumor metastasis, but not in the normal 
liver, 72 hours after AV22EL administration (Fig. 6B). 
Moreover, systemic administration of AV22EL led to E1A 
mRNA expression only in liver metastatic nodules, whereas 
other organs, such as spleen, kidney, intestine, lung, and 
nonmetastatic liver, exhibited no E1A expression (Fig. 6C, left). 
Similarly, systemic administration of AV-Luc, where luciferase 
activity was driven by the A3 3 promoter, showed activity 
exclusively in liver metastatic nodules (Fig. 6C, right).
To establish whether administration of AV22EL might affect 
liver function, we also assessed liver enzymes as a surrogate 
readout of liver toxicity. Growth of metastatic nodules in mice 
treated with PBS or control Ad-Pgal adenovirus decreased 
albumin levels while inducing an increase in aspartate 
aminotransferase and alkaline phosphatase levels (Fig. 6D). 
Interestingly, albumin levels seemed normal in mice treated 
with AV22EL, whereas the differences in albumin levels 
remained statistically significant between the "no tumor" group 
compared with the Ad-Pgal or PBS groups of mice (Fig. 6D). 
Aspartate aminotransferase levels also seemed normal in the 
AV22EL-treated group, whereas the Ad-Pgal group also 
exhibited diminished levels compared with the PBS-treated 
group (Fig. 6D). Alkaline phosphatase differences were not 
statistically significant between the different groups, although 
alkaline phosphatase levels in the AV22EL group were similar
Fig. 5. In vitro avid in vivo efficacy of AV22EL in combination or not with 5-FU. A, in vivo efficacy of AV22 EL on s.c. established LoVo tumors. Left, mice carrying established 
LoVo (n = 12) or SB2 tumors (/? = 6) were treated with AV22EL, whereas control mice (n = 8) received vehicle alone. AV22EL exerted a significant antitumor effect 
(P < 0.005 at day 35). Middle, Kaplan-Meier curve showing increased survival in mice induced byAV22EL treatment compared with the other groups. *, P < 0.01, when the 
AV22EL-treated group was compared with the vehicle-treated group. Right, intratumor replication of AV22EL compared with Ad-Luc. Adenovirus was injected intratumorally 
into LoVo tumors on day 0 at 1010 VP/tumor. Viral genome content was measured by quantitative real-time PCR. *, P < 0.05. B, a to c, in vitro cytocidal effect of AV22EL 
combined or not with 5-FU. Cells were incubated with two different concentrations of 5-FU or with AV22EL alone or in sequential combination. In the latter case, cells were 
transduced with AV22 EL at the indicated MOIs for 24 h and washed and then 5-FU was added for 4 additional days. Columns, mean; bars, SD. The asterisks indicate 
statistically significant differences compared with cells treated with 5-FU alone: *, P < 0.05; **, P < 0.01; ***, P < 0.001. C, in vivo efficacy of AV22EL combined or not with 
5-FU on s.c. established LoVo tumors. Left, mice carrying established LoVo tumors were treated with AV22EL alone (n = 6), 5-FU alone (/? = 4), and AV22EL/5-FU in 
combination (/? = 6). Control mice (/? = 4) were treated with vehicle alone. AV22EL combined or not with 5-FU showed a statistically significant antitumor effect (P < 0.005 at 
day 45). Right, Kaplan-Meier survival curve showing the increased survival induced byAV22EL treatment combined or not with 5-FU compared with the vehicle-treated 
group. *,P < 0.01.
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to those observed in the no tumor group (Fig. 6D). These data 
suggest that AV22EL not only was therapeutically efficient to 
inhibit metastatic growth but also was able to restore the 
normal function of the liver.
Discussion
Here, we show that a conditionally replicative oncolytic 
adenovirus based on the A33 promoter was able to inhibit the 
in vivo growth in nude mice of established colorectal carcinoma 
and eliminated established hepatic metastases. AV22EL was 
highly selective because it was completely ineffective on cells 
that did not express A3 3.
Most of the oncolytic viruses are developed based on 
promoters that can be active in more than a single cancer type 
to allow for a wider use without the therapeutic limitation of 
using the oncolytic virus in only one cancer type. This is the 
case for the CEA, COX-2, T-cell factor, and telomerase 
promoters that have been mentioned in Introduction. An 
additional CRAd based on a double heterologous promoter 
Ki67 and COX-2 showed significant oncolytic activity on s.c. 
established colorectal tumors, although its effectiveness on 
established hepatic metastases was not assessed (38). More 
recently, a CRAd expressing El A driven by the nonspecific Rous 
sarcoma virus promoter and the proapoptotic protein tumor 
necrosis factor-related apoptosis-inducing ligand was effective 
in inducing the elimination of established metastases obtained 
from colon carcinoma cells (39). The concern is that these 
promoters are active in different types of normal cells or under 
mild pathologic conditions, such as inflammation, limiting 
their systemic use due to their potential toxicity to normal 
organs.
Instead, oncolytic viruses such as AV22EL that are based on 
stringent, cancer type-specific promoters have the potential 
advantage of their strong attenuation in normal organs, 
increasing their effectiveness for systemic treatment of dissem­
inated disease. AV22EL has been cytocidal in vitro on colorectal 
carcinoma cells expressing A3 3 antigen growing in monolayers 
and as spheroids, indicating that AV22EL was able to penetrate 
the cell-cell adhesive interactions established in spheroid 
systems. On the other hand, AV22EL was rather ineffective on 
cells that did not express A33, such as melanoma and normal 
colorectal cells, which expressed very low levels of A3 3. Although 
this novel CRAd exhibited a slight lytic activity on hepatoma cells 
and certain human melanoma cells at the highest MOI, normal 
hepatocytes were completely refractory to AV22EL while they 
were lysed by the wild-type (WT) adenovirus.
The present data indicate that AV22EL exhibited several 
orders lower viral yield than WT adenovirus. In preliminary 
studies, we compared AV22EL with an adenoviral construct 
prepared with the JM17 backbone that includes the E3 region 
(40). Side by side comparison of the two CRAds showed that 
the presence of the entire E3 region was detrimental to CRAd 
activity, leading us to pursue the experiments with the CRAd 
lacking the E3 region. The detrimental effect of the entire E3 
region was consistent with previous data showing that the E3 
products 14.5K and 10.4K down-regulated E1A at the transla­
tional level (41). However, more recent evidence indicates that 
restoration of the E3 adenoviral death protein or even the entire 
E3 coding region might enhance CRAd activity (42-44), 
strongly suggesting that AV22EL lytic activity could be greatly 
improved by adding the adenoviral death protein coding region 
without losing tumor specificity.
To assess the potential capacity of AV22EL as a therapeutic 
agent in the clinics, we studied its combination with 5-FU that 
remains the mainstay of treatment for metastatic CRC. We did 
different combinations in vitro to establish (a) whether both 
compounds can result in additive or synergistic therapeutic 
effect, (b) if this effect might depend on the administration 
timing of both compounds, and (c) if they might render 
resistant cells sensitive to their combination. We observed that 
the combination of AV22EL and 5-FU was strongly effective 
in vitro even at concentrations where they were less effective as 
single agents. This improved in vitro inhibitory effect was 
observed in three different colon cancer cell types that differed 
in their A33 expression levels, mainly when the virus was 
administered before the chemotherapeutic agent, indicating 
that the virus was permissive for 5-FU effect. Despite the fact 
that we were unable to see enhanced therapeutic effect in vivo of 
their combination, the whole studies suggest that AV22EL can 
potentially induce an additive effect in combination with 5-FU 
against both p53 mutant (HT29 and T84) and WT (LoVo) 
colon carcinoma cells. This is of high importance as the cell 
cycle response to 5-FU treatment in colorectal carcinoma cells 
has been reported to be influenced by p53 status (45). It is 
expected that the therapeutic efficacy of AV22EL can be further 
improved by assessing different combination protocols with 
5-FU or additional novel chemotherapeutic agents.
Liver metastases remain a significant clinical problem in CRC 
with limited therapeutic options. Few oncolytic vectors were 
systemically administered to target hepatic metastasis derived 
from CRC. Systemic administration of AV22EL induced the 
disappearance of metastatic nodules in >90% of mice and 
seemed to restore normal levels of hepatic enzymes. Moreover, 
human hepatocytes were completely refractory to AV22EL and 
autopsy done on mice that received AV22EL systemically 
confirmed the absence of hepatic toxicity. Because murine cells 
are not permissive for adenoviral replication, it was of relevance 
in terms of viral toxicity the information obtained from the use 
of Onyx-15 in the clinics, a type 5 oncolytic adenovirus that is 
attenuated due to the deletion in El b 55K gene (46). Recent data 
show that its administration through the hepatic artery to 
patients with metastatic CRC involving the liver exerted only 
minimal toxicity (47). Because fresh human CRC samples 
exhibited high expression levels of coxsackie-adenoviral recep­
tor, the natural receptor of adenovirus type 5 (48), it can be 
proposed that oncolytic viruses based on adenovirus type 5 with 
strong and selective lytic capacity, such as AV22EL, which is 
highly attenuated in hepatic cells, might represent an alternative 
to existing oncolytic viruses for systemic administration.
The human A33 antigen is a Mr 43,000 cell membrane 
glycoprotein that has become a target for antibody immuno­
therapy due to its restricted localization in colon cancer as well 
as in metastatic lesions of the same origin (24). The humanized 
antibody (huA33) has led to the initiation of a phase I clinical 
trials with encouraging results (26). The iodinated antibody 
has shown selective localization and deep penetration even in 
large necrotic tumors, suggesting that huA33 might become 
a therapeutic tool for cancer immunotherapy (24). However, 
in two clinical studies, patients developed anti-huA33 anti­
bodies, limiting its potential therapeutic effect and the full 
manifestation of its potential clinical toxicities (49, 50),
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Fig. 6. In vivo efficacy of AV22EL on established hepatic metastases. A representative photographs of mice carrying LoVo tumors treated or not with AV22EL. Arrow, 
light macroscopic photographs showing the presence of metastatic nodules in PBS-treated and Ad-p.gal - treated mice. Top, AV22EL-treated mice show the liver clear 
of metastatic nodules. H &.E staining of human liver sections. Bottom, arrows, LoVo tumors display areas with glandular-like arrangement of tumor cells. Magnification, 
x200. Right, comparison of metastases number. Number of metastases were determined at the end of the experiments 14 d after administration of the first viral dose. 
B, immunohistochemical detection of hexon protein in metastatic areas (A4) located in the liver (£). Arrows, positive staining in metastatic cells and negative staining in 
hepatocytes. The areas in the box are further examined at higher magnification. Magnifications, x 200 and x400. C, E1A mRNA expression in different organs following 
AV22 EL administration. PCR analysis was done on total RNAs obtained from different organs 72 h after injection of AV22 EL or PBS via tail vein. Right, tissue distribution of 
AV-Luc. Six mice were administered i.v. 1O10 vp of AV-Luc and 10° vp of Ad-CMV Renilla. Forty-eight hours later, luciferase activity in various tissues and liver metastatic 
nodules was determined. Results are expressed as mean of luciferase activity in light units per milligram of protein. Bars, SD. D, comparison of serum liver chemistries: hepatic 
panel function was determined at the end of the experiments 14 d after administration of the first viral dose. Serum enzyme levels are reported in units/mL. Albumin level is 
reported in g/dL. Columns, mean; bars, SD. *, statistically significant differences to no tumor mice (P < 0.05).
suggesting that a less immunogenic compound might be 
necessary.
Here, we have shown the therapeutic efficacy of a novel 
CRAd whose replication is driven by the A3 3 promoter, 
providing an additional strategy that makes use of the tissue­
specific expression of this protein. Despite the fact that AV22EL 
exhibited lower replication capacity than WT adenovirus 
in vitro, it showed intratumor replicating capacity similar to
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that attained in breast cancer for a CRAd that targets the G, -S 
checkpoint (Ad-dl922-947) and higher than Ad-Onyx-O17 that 
targets p53 (36). Thus, AV22EL was highly effective on primary 
tumors and hepatic metastasis of CRC with no cytocidal effect 
on normal colon derived cells, could be combined with current 
chemotherapeutic treatments, restored the normal hepatic 
function after the elimination of hepatic metastasis, and after 
systemic administration was strictly active in hepatic metasta­
ses, avoiding normal organs. Given the evidence of the mild 
adverse effects of oncolytic adenovirus therapeutics, we believe 
that AV22EL might become a useful tool for treatment of 
patients with CRC.
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